UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (427) 427
science & technology (418) 418
simvastatin (415) 415
life sciences & biomedicine (383) 383
male (235) 235
simvastatin - therapeutic use (227) 227
female (212) 212
middle aged (187) 187
simvastatin - economics (169) 169
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (151) 151
statins (144) 144
aged (138) 138
pharmacology & pharmacy (126) 126
cholesterol (124) 124
cost-benefit analysis (122) 122
anticholesteremic agents - therapeutic use (115) 115
hydroxymethylglutaryl-coa reductase inhibitors - economics (110) 110
adult (103) 103
antilipemic agents (102) 102
simvastatin - administration & dosage (101) 101
risk factors (99) 99
general & internal medicine (89) 89
anticholesteremic agents - economics (88) 88
medicine, general & internal (88) 88
hypercholesterolemia - drug therapy (83) 83
atorvastatin calcium (79) 79
abridged index medicus (77) 77
atorvastatin (74) 74
treatment outcome (74) 74
drug costs (72) 72
cholesterol, ldl - blood (71) 71
cardiovascular disease (70) 70
cardiovascular diseases - prevention & control (70) 70
analysis (69) 69
cardiovascular system & cardiology (65) 65
heptanoic acids - therapeutic use (63) 63
pyrroles - therapeutic use (63) 63
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (59) 59
research (59) 59
animals (58) 58
cardiac & cardiovascular systems (58) 58
drug therapy (58) 58
lipids (54) 54
cardiovascular diseases (53) 53
drugs (52) 52
heptanoic acids - economics (52) 52
pharmaceutical industry (52) 52
pyrroles - economics (52) 52
lovastatin - therapeutic use (51) 51
hypercholesterolemia (49) 49
hypolipidemic agents - therapeutic use (49) 49
simvastatin - pharmacology (47) 47
simvastatin - adverse effects (46) 46
medicine (45) 45
medicine & public health (45) 45
drug therapy, combination (44) 44
ezetimibe (44) 44
cardiovascular agents (43) 43
prevention (43) 43
retrospective studies (43) 43
aged, 80 and over (42) 42
pravastatin - therapeutic use (41) 41
cholesterol - blood (40) 40
health aspects (40) 40
low density lipoproteins (39) 39
clinical trials (37) 37
health care sciences & services (37) 37
mortality (37) 37
hyperlipidemias - drug therapy (36) 36
internal medicine (36) 36
lovastatin - economics (36) 36
pravastatin (36) 36
anticholesteremic agents - administration & dosage (35) 35
cardiology (35) 35
care and treatment (35) 35
diabetes (34) 34
drugs, generic - economics (34) 34
cardiovascular diseases - economics (33) 33
coronary disease - prevention & control (33) 33
hypercholesterolemia - economics (33) 33
medical research (33) 33
studies (33) 33
time factors (33) 33
health policy & services (32) 32
hypercholesterolemia - blood (32) 32
pravastatin - economics (32) 32
coronary heart disease (31) 31
dose-response relationship, drug (30) 30
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (30) 30
hypolipidemic agents - economics (30) 30
research article (30) 30
cost-effectiveness (29) 29
heart attacks (29) 29
lovastatin - analogs & derivatives (29) 29
cardiovascular diseases - drug therapy (28) 28
heptanoic acids - administration & dosage (28) 28
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (28) 28
medicine, research & experimental (28) 28
nutritional and metabolic diseases (28) 28
pharmacology (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (642) 642
Spanish (9) 9
German (7) 7
Swedish (6) 6
Dutch (4) 4
Norwegian (4) 4
Russian (4) 4
Danish (3) 3
Portuguese (3) 3
French (1) 1
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The European journal of health economics, ISSN 1618-7598, 6/2012, Volume 13, Issue 3, pp. 365 - 374
...) provides comprehensive lipid management. We adapted a decisionanalytic model to evaluate the economic value... 
Maintenance costs | Sensitivity analysis | Secondary prevention | Lipids | Triglycerides | Diabetes | Dosage | Cholesterols | Coronary artery disease | Congenital heart defects | Economic Policy | Laropiprant | Statistics for Life Sciences, Medicine, Health Sciences | Simvastatin | Health Informatics | I10 | Public Health/Gesundheitswesen | Medicine & Public Health | Statistics for Business/Economics/Mathematical Finance/Insurance | Public Finance & Economics | Dyslipidaemia | Extended-release niacin | Hypercholesterolaemia | Cost-effectiveness | Economics | Social Sciences | Life Sciences & Biomedicine | Business & Economics | Health Care Sciences & Services | Health Policy & Services | Science & Technology | Simvastatin - therapeutic use | Humans | Middle Aged | Male | Simvastatin - economics | Models, Economic | Indoles - administration & dosage | Niacin - administration & dosage | Niacin - therapeutic use | Life Expectancy | Aged, 80 and over | Female | Indoles - economics | Dyslipidemias - economics | Dyslipidemias - drug therapy | Risk Assessment | Simvastatin - administration & dosage | Anticholesteremic Agents - economics | Niacin - economics | Drug Therapy, Combination - economics | Health Care Costs | Hypolipidemic Agents - economics | Anticholesteremic Agents - therapeutic use | Secondary Prevention - economics | Anticholesteremic Agents - administration & dosage | Cost-Benefit Analysis | Hypolipidemic Agents - administration & dosage | Indoles - therapeutic use | Aged | Hypolipidemic Agents - therapeutic use | Germany | Low density lipoproteins | Coronary heart disease | Niacin | Cholesterol | Antilipemic agents | Prevention | Hypercholesterolemia | Analysis | Heart diseases | Statins | Studies | Mortality | Cardiovascular disease | Cost analysis | Economic statistics | Benefit cost analysis | Index Medicus | Public Health | Original Paper | Gesundheitswesen | Statistics for Business | Insurance | Mathematical Finance
Journal Article
The European journal of health economics, ISSN 1618-7598, 4/2010, Volume 11, Issue 2, pp. 177 - 184
Background Drug costs are increasing despite the introduction of cheaper generic drugs. The aim of the present study was to analyse the entire costs of... 
Myocardial infarction | Heart | Total costs | Prescription drugs | Hospital costs | Mortality | Angiotensin converting enzyme inhibitors | Experimentation | Cost analysis | Drug costs | Economic Policy | I18 | I00 | Public Finance & Economics | Record linkage | Public Health/Gesundheitswesen | Out-patient costs | Economics / Management Science | Economics | Social Sciences | Life Sciences & Biomedicine | Business & Economics | Health Care Sciences & Services | Health Policy & Services | Science & Technology | Hospital Costs | Platelet Aggregation Inhibitors - economics | Simvastatin - therapeutic use | Myocardial Infarction - mortality | Prognosis | Age Factors | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Simvastatin - economics | Catheter Ablation - economics | Angiotensin-Converting Enzyme Inhibitors - economics | Myocardial Infarction - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Atherectomy - economics | Ticlopidine - economics | Adrenergic beta-Antagonists - economics | Adult | Female | Myocardial Infarction - economics | Registries | Medical Record Linkage | Diabetes Mellitus - mortality | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Risk Factors | Anticholesteremic Agents - economics | Proportional Hazards Models | Treatment Outcome | Coronary Artery Bypass - economics | Drug Therapy, Combination - economics | Sweden - epidemiology | Ticlopidine - analogs & derivatives | Anticholesteremic Agents - therapeutic use | Myocardial Infarction - drug therapy | Health Care Costs - statistics & numerical data | Aged | Generic drugs | Coronary artery bypass | Analysis | Simvastatin | Surgery | Diabetes | Drug therapy | Heart attack | Medical care, Cost of | Studies | Heart attacks | Health care expenditures | Health economics | Index Medicus | Public Health, Global Health, Social Medicine and Epidemiology | Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
Journal Article
The European journal of health economics, ISSN 1618-7598, 8/2012, Volume 13, Issue 4, pp. 445 - 450
Background The economic evaluation of statins has undergone a development from risk-factor-based models to modeling of hard end points in clinical trials with a shift back to risk-factor models... 
Producer surplus | Consumer surplus | Health care costs | Capital costs | Total surplus | Economic value | Cost estimates | Cost savings | Cholesterols | Production costs | Economic Policy | I18 | Medicine & Public Health | Statistics for Life Sciences, Medicine, Health Sciences | Statistics for Business/Economics/Mathematical Finance/Insurance | Simvastatin | Public Finance & Economics | Health Informatics | Cardiovascular disease | Public Health/Gesundheitswesen | Economics | Social Sciences | Life Sciences & Biomedicine | Business & Economics | Health Care Sciences & Services | Health Policy & Services | Science & Technology | Quality-Adjusted Life Years | Simvastatin - therapeutic use | Costs and Cost Analysis | Cardiovascular Diseases - prevention & control | Humans | Hyperlipidemias - drug therapy | Risk Factors | Cost of Illness | Hyperlipidemias - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Simvastatin - economics | Drug Prescriptions - statistics & numerical data | Hyperlipidemias - mortality | Sweden | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Health Policy | Social aspects | Statins | Innovations | Antilipemic agents | Economic models | Research & development--R&D | Cost control | Studies | Health economics | Health care expenditures | Economic theory | Health care industry | Drug therapy | Cost analysis | Index Medicus | Medicin och hälsovetenskap
Journal Article
Heart (British Cardiac Society), ISSN 1355-6037, 04/2017, Volume 103, Issue 7, pp. 483 - 499
ObjectiveThere is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower... 
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - therapeutic use | Dyslipidemias - complications | Tablets | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Simvastatin - economics | Models, Economic | Time Factors | Computer Simulation | Adult | Female | Dyslipidemias - economics | Hypertension - diagnosis | Hypertension - economics | Dyslipidemias - diagnosis | Antihypertensive Agents - economics | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - economics | Losartan - economics | Quality-Adjusted Life Years | Cardiovascular Diseases - etiology | Dyslipidemias - drug therapy | Primary Prevention - economics | Risk Assessment | Administration, Oral | Risk Factors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hydrochlorothiazide - economics | Amlodipine - therapeutic use | Cost-Benefit Analysis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Losartan - therapeutic use | Primary Prevention - methods | Hypertension - complications | Aged | Amlodipine - economics | Hydrochlorothiazide - therapeutic use | Drug Combinations | Prevention | Cardiovascular diseases | Risk assessment | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
The American heart journal, ISSN 0002-8703, 08/2019, Volume 214, pp. 77 - 87
There is underutilization of appropriate medications for secondary prevention of cardiovascular disease (CVD). Usual care (UC) was compared to polypill-based... 
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Drug Costs | Platelet Aggregation Inhibitors - economics | Nutrition Surveys | United States | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Secondary Prevention - methods | Cost Savings | Renin-Angiotensin System | Life Expectancy | Adrenergic beta-Antagonists - economics | Cardiovascular Diseases - mortality | Female | Atenolol - economics | Aspirin - economics | Stroke - mortality | Budgets | Cardiovascular Diseases - economics | Stroke - prevention & control | Stroke - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Ramipril - economics | Secondary Prevention - statistics & numerical data | Medication Adherence | Secondary Prevention - economics | Cost-Benefit Analysis | Drug Combinations | Prevention | Medical policy | Aspirin | Analysis | Angiotensin | Models | Cardiovascular diseases | Heart attack | Statins | Medical care, Cost of | Health care | Heart | Drugs | Cost reduction | Cardiovascular disease | Aldosterone | Renin | Cost effectiveness | Population | Blood pressure | Trends | Drug dosages | Enzymes | Stroke | Sensitivity analysis | Computer simulation | Simvastatin | Health care policy | Atenolol | Low density lipoprotein | Disease prevention | Health care expenditures | Atorvastatin | Diabetes | Cost analysis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2003, Volume 21, Issue Suppl. 1, pp. 13 - 23
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2003, Volume 21, Issue Suppl. 1, pp. 1 - 11
Journal Article
Diabetes care, ISSN 1935-5548, 06/2003, Volume 26, Issue 6, pp. 1796 - 1801
Journal Article
PharmacoEconomics, ISSN 1170-7690, 07/1998, Volume 14, Issue 1, pp. 59 - 70
.... The relative resource utilisation and cost associated with the use of reductase inhibitors of different LDL-C lowering efficacy are unknown, but are major health and economic concerns... 
Guideline-utilisation | Fluvastatin, therapeutic-use | Cost-analysis | Lovastatin, therapeutic-use | Randomised-controlled-trials | Drug-utilisation | Pharmacoeconomics | Simvastatin, therapeutic-use | Clinical-trial-design | Atorvastatin, therapeutic-use | Hmg-coa-reductase-inhibitors, therapeutic-use | Hypercholesterolaemia, treatment | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Simvastatin - therapeutic use | United States | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Simvastatin - economics | Hypercholesterolemia - drug therapy | Fatty Acids, Monounsaturated - therapeutic use | Female | Pyrroles - economics | Indoles - economics | Pyrroles - therapeutic use | Lovastatin - therapeutic use | Heptanoic Acids - economics | Anticholesteremic Agents - economics | Hypercholesterolemia - economics | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Lovastatin - economics | Cost-Benefit Analysis | Indoles - therapeutic use | Aged | Health Policy - economics | Fatty Acids, Monounsaturated - economics | Pharmacoeconomics; Guideline-utilisation; Hypercholesterolaemia; Fluvastatin; Lovastatin; Atorvastatin; Simvastatin; Cost-analysis; Randomised-controlled-trials; Clinical-trial-design; Hmg-coa-reductase-inhibitors; Drug-utilisation | Health technology assessment
Journal Article